Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: ALB stock price vs ECL: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ECL's multiple
Needs ECL P/S.
Implied fair value · at ALB's multiple
Needs Revenue / share, ALB P/S.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
ALBEMARLE CORPORATION · implied price per share
At least 3 of the last 5 annual free-cash-flow observations must be positive.
ECOLAB INC. · implied price per share
Bear
$44.93
Base
$57.49
Bull
$73.86
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
FMC CORP
ALB vs FMC
CHEMICAL & MINING CO OF CHILE INC
ALB vs SQM
Avalo Therapeutics, Inc.
ALB vs AVTX
LITHIUM AMERICAS CORP.
ALB vs LAC
RPM INTERNATIONAL INC/DE/
ALB vs RPM
PPG INDUSTRIES INC
ALB vs PPG
Procter & Gamble Company
ALB vs PG
COLGATE PALMOLIVE CO
ALB vs CL
CLOROX CO /DE/
ALB vs CLX
KIMBERLY CLARK CORP
ALB vs KMB
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe ALB can reverse its -4.4% revenue decline and restore positive operating margins from -7.1%, then the current price may offer upside relative to the P/S-implied value; otherwise, ECL-like quality is not evident in the data, so the cheaper multiple may be justified.
ALB’s current price of $117.64 sits well below the P/S-implied price of $212.01, implying 80.2% upside on that basis. However, the stock is already above the upper end of ECL-implied range at $211.85 only by a large margin? No—the provided ECL-implied range is $62.83 to $211.85 and ALB is actually below the top end, while also sitting inside its historical band of $105.88 to $129.40, suggesting the market is valuing ALB closer to its own trading history than to ECL’s multiple.
Supporting Metrics
